文献速递炎症性肠病

炎症性肠病患者停用抗TNF药物后的演变:一项多中心长期随访研究

Evolution After Anti-TNF Discontinuation in Patients With Inflammatory Bowel Disease: A Multicenter Long-Term Follow-Up Study.
PubMed 文献 · Am J Gastroenterol · 2016-12-13

这项回顾性、观察性、多中心研究纳入1,055例达到临床缓解后停用抗TNF药物的炎症性肠病患者,评估复发风险及相关因素。克罗恩病和溃疡性结肠炎患者每患者年复发率分别为19%和17%,深缓解者均为每患者年19%。复发后使用同一抗TNF药物再治疗有效(80%应答)且安全。

要点

  • 停用抗TNF后克罗恩病和溃疡性结肠炎每患者年复发率分别为19%和17%。
  • 克罗恩病中阿达木单抗较英夫利西单抗、选择性停药及因不良事件停药与更高复发风险相关。
  • 复发后使用同一抗TNF药物再治疗80%应答且安全。

核心结论

  • 停用抗TNF后炎症性肠病复发率具有临床相关性,已识别部分复发预测因素,同一抗TNF药物再治疗有效且安全。

研究设计与样本

  • 回顾性、观察性、多中心研究,纳入1,055例达到临床缓解后停用抗TNF药物的炎症性肠病患者。

主要发现

  • 克罗恩病患者每患者年复发率为19%,溃疡性结肠炎患者为17%。
  • 克罗恩病和溃疡性结肠炎深缓解患者每患者年复发率均为19%。
  • 克罗恩病中,阿达木单抗较英夫利西单抗(HR=1.29;95%CI=1.01-1.66)、选择性停用抗TNF较降阶梯策略(HR=1.90;95%CI=1.07-3.37)、因不良事件停药较降阶梯策略(HR=2.33;95%CI=1.27-2.02)、结肠定位较回肠定位(HR=1.51;95%CI=1.13-2.02)、狭窄型行为较炎症型行为(HR=1.5;95%CI=1.09-2.05)与更高复发风险相关。
  • 克罗恩病中,停药后使用免疫调节剂(HR=0.67;95%CI=0.51-0.87)和年龄(HR=0.98;95%CI=0.97-0.99)为保护因素。
  • 溃疡性结肠炎患者中无任何因素具有预测性;复发后使用同一抗TNF药物再治疗有效(80%应答)且安全。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The aims of this study were to assess the risk of relapse after discontinuation of anti-tumor necrosis factor (anti-TNF) drugs in patients with inflammatory bowel disease (IBD), to identify the factors associated with relapse, and to evaluate the overcome after retreatment with the same anti-TNF in those who relapsed. METHODS: This was a retrospective, observational, multicenter study. IBD patients who had been treated with anti-TNFs and in whom these drugs were discontinued after clinical remission was achieved were included. RESULTS: A total of 1,055 patients were included. The incidence rate of relapse was 19% and 17% per patient-year in Crohn's disease and ulcerative colitis patients, respectively. In both Crohn's disease and ulcerative colitis patients in deep remission, the incidence rate of relapse was 19% per patient-year. The treatment with adalimumab vs. infliximab (hazard ratio (HR)=1.29; 95% confidence interval (CI)=1.01-1.66), elective discontinuation of anti-TNFs (HR=1.90; 95% CI=1.07-3.37) or discontinuation because of adverse events (HR=2.33; 95% CI=1.27-2.02) vs. a top-down strategy, colonic localization (HR=1.51; 95% CI=1.13-2.02) vs. ileal, and stricturing behavior (HR=1.5; 95% CI=1.09-2.05) vs. inflammatory were associated with a higher risk of relapse in Crohn's disease patients, whereas treatment with immunomodulators after discontinuation (HR=0.67; 95% CI=0.51-0.87) and age (HR=0.98; 95% CI=0.97-0.99) were protective factors. None of the factors were predictive in ulcerative colitis patients. Retreatment of relapse with the same anti-TNF was effective (80% responded) and safe. CONCLUSIONS: The incidence rate of inflammatory bowel disease relapse after anti-TNF discontinuation is relevant. Some predictive factors of relapse after anti-TNF withdrawal have been identified. Retreatment with the same anti-TNF drug was effective and safe.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Casanova MJ, Chaparro M, García-Sánchez V, et al. Evolution After Anti-TNF Discontinuation in Patients With Inflammatory Bowel Disease: A Multicenter Long-Term Follow-Up Study. Am J Gastroenterol. 2016. PMID: 27958281. doi:10.1038/ajg.2016.569

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。